ArticleInternational journal of chronic obstructive pulmonary disease2025
Evaluation of the Efficacy of Jiangqi Dingchuan Pill Based on Network Pharmacology Analysis and Cigarette Smoke and Lipopolysaccharide Induced Chronic Obstructive Pulmonary Disease Rat Model.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Jiangqi Dingchuan Pill (JDP) is a patent Chinese medicine in the treatment of asthma. JDP consists of six herbal drugs, namely, Ephedrae Herba, Mori Cortex, Citri Reticulatae Pericarpium, Perillae Fructus, Descurainiae Semen, Sinapis Semen. Objective: To employ the tools of network pharmacology and in vivo experiments, exploring the possible mechanism of JDP in treating chronic obstructive pulmonary disease (COPD). Materials and Methods: Chemical constituents of JDP, collection of targets of COPD, target prediction were conducted, and then network pharmacological analysis was performed based on protein-protein interaction (PPI). The cigarette smoke and lipopolysaccharide-induced COPD model was applied to assess the effects of JDP. Rats were randomly divided into five groups (n = 8), ie, a sham group, a COPD-control group, two COPD groups treated with different doses of JDP (1.26 and 2.52 g/kg/d, respectively), and one COPD group treated with aminophylline (54 mg/kg/d). Pulmonary functions were assessed. The inflammatory cytokines in bronchial alveolar lavage fluid (BALF) were quantified using enzyme-linked immunosorbent assay (ELISA). The expression of matrix metalloprotein-9 (MMP-9) was quantified using Western blot. Results: A total of 108 genes were found to be the main target genes regulated by JDP in the treatment of COPD, according to PPI analysis. Compared with the COPD-control group, rats in the JDP group exhibited amelioration in lung function, including 20 ms forced expiratory volume/forced vital capacity, maximal mid-expiratory flow curve, and airway resistance (all Conclusion: This study explored the effects and its mechanisms of JDP in COPD treatment. JDP exhibited therapeutic potential as a COPD intervention drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.